Screening adults for type 2 diabetes: A review of the evidence for the US Preventive Services Task Force

被引:78
作者
Harris, R
Donahue, K
Rathore, SS
Frame, P
Woolf, SH
Lohr, KN
机构
关键词
D O I
10.7326/0003-4819-138-3-200302040-00015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Type 2 diabetes mellitus is associated with a heavy burden of suffering. Screening for diabetes is controversial. Purpose: To examine the evidence that screening and earlier treatment are effective in reducing morbidity and mortality associated with diabetes. Data Sources: MEDLINE, the Cochrane Library, reviews, and experts, all of which addressed key questions about screening. Study Selection: Studies that provided information about the existence and length of an asymptomatic phase of diabetes; studies that addressed the accuracy and reliability of screening tests; and randomized, controlled trials with health outcomes for various treatment strategies were selected. Data Extraction: Two reviewers abstracted relevant information using standardized abstraction forms and graded articles according to U.S. Preventive Services Task Force criteria. Data Synthesis: No randomized, controlled trial of screening for diabetes has been performed. Type 2 diabetes mellitus includes an asymptomatic preclinical phase; the length of this phase is unknown. Screening tests can detect diabetes in its preclinical phase. Over the 10 to 15 years after clinical diagnosis, tight glycemic control probably reduces the risk for blindness and end-stage renal disease, and aggressive control of hypertension, lipid therapy, and aspirin use reduce cardiovascular events. The magnitude of the benefit is larger for cardiovascular risk reduction than for tight glycemic control. The additional benefit of starting these treatments in the preclinical phase, after detection by screening, is uncertain but is probably also greater for cardiovascular risk reduction. Conclusions: The interventions that are most clearly beneficial during the preclinical phase are those that affect the risk for cardiovascular disease. The magnitude of additional benefit of initiating tight glycemic control during the preclinical phase is uncertain but probably small.
引用
收藏
页码:215 / 229
页数:15
相关论文
共 140 条
  • [61] Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension:: the Nordic Diltiazem (NORDIL) study
    Hansson, L
    Hedner, T
    Lund-Johansen, P
    Kjeldsen, SE
    Lindholm, LH
    Syvertsen, JO
    Lanke, J
    de Faire, U
    Dahlöf, B
    Karlberg, BE
    [J]. LANCET, 2000, 356 (9227) : 359 - 365
  • [62] Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial
    Hansson, L
    Lindholm, LH
    Niskanen, L
    Lanke, J
    Hedner, T
    Niklason, A
    Luomanmäki, K
    Dahlöf, B
    de Faire, U
    Mörlin, C
    Karlberg, BE
    Wester, PO
    Björck, JE
    [J]. LANCET, 1999, 353 (9153) : 611 - 616
  • [63] Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial
    Hansson, L
    Zanchetti, A
    Carruthers, SG
    Dahlöf, B
    Elmfeldt, D
    Julius, S
    Ménard, J
    Rahn, KH
    Wedel, H
    Westerling, S
    [J]. LANCET, 1998, 351 (9118) : 1755 - 1762
  • [64] SCREENING FOR NIDDM - WHY IS THERE NO NATIONAL PROGRAM
    HARRIS, MI
    MODAN, M
    [J]. DIABETES CARE, 1994, 17 (05) : 440 - 444
  • [65] Is there a glycemic threshold for mortality risk?
    Harris, MI
    Eastman, RC
    [J]. DIABETES CARE, 1998, 21 (03) : 331 - 333
  • [66] ONSET OF NIDDM OCCURS AT LEAST 4-7 YR BEFORE CLINICAL-DIAGNOSIS
    HARRIS, MI
    KLEIN, R
    WELBORN, TA
    KNUIMAN, MW
    [J]. DIABETES CARE, 1992, 15 (07) : 815 - 819
  • [67] Comparison of diabetes diagnostic categories in the US population according to 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria
    Harris, MI
    Eastman, RC
    Cowie, CC
    Flegal, KM
    Eberhardt, MS
    [J]. DIABETES CARE, 1997, 20 (12) : 1859 - 1862
  • [68] Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults - The Third National Health and Nutrition Examination Survey, 1988-1994
    Harris, MI
    Flegal, KM
    Cowie, CC
    Eberhardt, MS
    Goldstein, DE
    Little, RR
    Wiedmeyer, HM
    Byrd-Holt, DD
    [J]. DIABETES CARE, 1998, 21 (04) : 518 - 524
  • [69] HARRIS R, 2002, 19 AG HEALTHC RES QU
  • [70] Current methods of the US Preventive Services Task Force - A review of the process
    Harris, RP
    Helfand, M
    Woolf, SH
    Lohr, KN
    Mulrow, CD
    Teutsch, SM
    Atkins, D
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2001, 20 (03) : 21 - 35